Fueled by four new product launches over the last two years, Genentech Inc. recorded a healthy first quarter in terms of both dollars and data. (BioWorld Today)

Northfield Laboratories Inc.'s stock jumped 31.6 percent Monday after an independent data monitoring committee gave the go-ahead for the ongoing Phase III trial of PolyHeme. (BioWorld Today)

The path to market for Genelabs Technologies Inc.'s lupus drug Prestara narrowed this week when another Phase III trial failed to meet the primary endpoint. (BioWorld Today)

Serono SA had a double dose of news Wednesday, stopping two of its Phase III programs: onercept for psoriasis, and newly partnered product Canvaxin for Stage IV melanoma. (BioWorld Today)

In what has proved to be a slow and somewhat bumpy road for gene therapy research, one company - Avigen Inc. - is gracefully bowing out in order to focus on more traditional drug development. (BioWorld Today)

Establishing a second major collaboration, this time in the fields of cancer and tissue repair, Curis Inc. and Genentech Inc. joined forces to discover and develop small-molecule modulators of an undisclosed pathway. (BioWorld Today)